COVID-19 in Hematology Research Grant
The call for LOIs is now closed.
This ad hoc EHA Research Grant call responds to the current COVID-19 pandemic and reflects EHA’s commitment to supporting quality research projects in this area.
The grant is intended for basic, translational or clinical research questions that address:
- aspects of COVID-19 infection in malignant and benign hematologic disorders OR
- hematological and immunological manifestations in COVID-19 infection
Amount and duration of the grant
At this stage, no specific budgetary restrictions apply but funding will be in the range of €50.000 – €120.000 for a duration of 1 year.
- The home or host institute must be in Europe
- EHA’s Terms and Conditions apply to this grant
Collaborative projects are encouraged. Collaborative projects involving research between hematology and other medical disciplines will also be evaluated. If one of the collaborators is outside Europe, at least 50% of the research must be performed in Europe.
How to apply
The call entails a two-step procedure. First to be submitted, a letter of intent (LoI) briefly outlining the scope of the project in no more than 1500 words. LoIs should be structured as follows: Background, Rationale, Aims, Methods, Expected results, and Budget overview. In addition, a concise CV for each PI should also be submitted. These documents should be collated into 1 pdf, named <PI last name.PI first name_PI institute.pdf>, and should be sent to email@example.com before May 5, 2020 (15:00 CEST).
LOIs will be screened by the EHA’s Fellowships & Grants Committee members and experts in infectious disease for novelty, relevance to the hematology community, feasibility, and accuracy. Highest ranked applicants will then be invited to submit a full proposal by June 2, 2020 (15:00 CEST).
With the help of external reviewers, the F&G committee and the experts in infectious diseases will identify which applications are most promising. The applicants will be interviewed via video conference on June 22, 2020.